Welcome to our dedicated page for REVVITY SEC filings (Ticker: RVTY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Revvity, Inc.'s SEC filings document operating results, governance matters and capital-structure disclosures for a Massachusetts-incorporated life sciences and diagnostics company. Its 8-K reports furnish quarterly and annual financial results, preliminary performance updates, Regulation FD investor presentation materials and other material-event disclosures.
Proxy and annual-meeting filings describe director elections, auditor ratification, advisory executive-compensation votes and shareholder-approved bylaw amendments, including the ability of holders of 25% of the company's stock to call a special meeting. Other current reports identify registered securities, including RVTY common stock and 1.875% notes due 2026 listed on the New York Stock Exchange, as well as officer appointments and related governance changes.
REVVITY, INC. (RVTY) director Alexis P. Michas reported a bona fide gift of 285 shares of common stock made by The Cayre and Alexis Michas Foundation Corp. to a charitable organization. Following this, the foundation holds 6,985 shares indirectly, Michas holds 63,780 shares directly (including dividend-related shares in a Deferred Compensation Plan), and a spouse IRA holds 500 shares indirectly. The reporting person disclaims beneficial ownership of the foundation-held shares except to any extent of pecuniary interest.
REVVITY, INC. (RVTY) officer Joel S. Goldberg reported two related stock transfers involving Common Stock. Goldberg made a bona fide gift of 27,785 shares from his direct holdings, reducing his directly held shares to 13,729. The same 27,785 shares were received as a gift by an entity classified as indirectly owned, the Goldberg Irrevocable 2021 Trust, which held 91,494 shares after the transfer. The trust is for the sole benefit of Goldberg’s children, with his spouse as trustee, and Goldberg disclaims beneficial ownership of those trust shares except to any pecuniary interest, if any.
Prahlad R. Singh, President, Chief Executive Officer and Director of REVVITY, INC. (RVTY), reported a series of bona fide gift transactions in common stock on 2026-08-13. He transferred 7,636 shares to an irrevocable trust for his children and separately 59,650 shares to the Singh Marital Trust of 2026, both at a reported price of $0.00 per share. After these transfers, the Singh Family Trust of 2021 held 54,219 shares and the Singh Marital Trust of 2026 held 59,650 shares. Singh disclaims beneficial ownership of the gifted securities except to the extent of any pecuniary interest he may have.
T. Rowe Price Investment Management, Inc. reports beneficial ownership of common stock of Revvity Inc. as an institutional investment adviser. The firm reports beneficial ownership of 18,269,089 shares of common stock, representing 16.4% of the outstanding class.
T. Rowe Price Investment Management states it has sole voting power over 17,089,376 shares and sole dispositive power over 18,269,089 shares, with no shared voting or dispositive power. The filing explains that dividends and sale proceeds are ultimately for the benefit of its individual and institutional clients, who may revoke delegated discretionary authority.
The disclosure notes that T. Rowe Price Capital Appreciation Fund, for which T. Rowe Price Investment Management serves as investment adviser, holds 11,237,061 shares, representing 10.1% of the class. T. Rowe Price Investment Management expressly denies that this disclosure should be construed as an admission that it is the beneficial owner of the securities.
T. Rowe Price Associates, Inc. filed Amendment No. 4 to a Schedule 13G reporting beneficial ownership of common stock of Revvity Inc. As of June 30, 2026, T. Rowe Price Associates reported beneficial ownership of 5,526,874 shares of Revvity Inc common stock, representing 5.0% of the class.
The firm reported sole voting power over 5,508,363 shares and sole dispositive power over 5,526,874 shares, with no shared voting or dispositive power. T. Rowe Price Associates expressly stated that this filing should not be construed as an admission that it is the beneficial owner of these securities, and that such beneficial ownership is denied.
Revvity, Inc. reported second-quarter 2026 revenue of $729.7 million, up about 1% from $720.3 million a year earlier. Life Sciences revenue declined to $358.7 million while Diagnostics rose to $371.0 million, driven by Reproductive Health and favorable foreign exchange, offset by softer Software and Immunodiagnostics.
Gross margin improved to 57.1% from 54.5%, helped by $16.2 million of U.S. tariff refunds and product mix, but operating income from continuing operations was roughly flat at $89.3 million as $35.5 million of restructuring and other costs and higher SG&A offset the margin gains. Q2 net income was $51.8 million and diluted EPS was $0.47.
For the first six months of 2026, revenue reached $1.44 billion versus $1.39 billion, and operating cash flow from continuing operations increased to $317.8 million. Cash and cash equivalents were $1.02 billion against total debt of $3.22 billion. The company acquired Advanced Chemistry Development Inc. for $72.0 million plus up to $8.0 million in earn-out, continued share repurchases, paid a quarterly dividend of $0.07 per share, and agreed to divest its China Immunodiagnostics business, which represented about 6% of 2025 revenue.
Revvity, Inc. reported second-quarter 2026 results and outlined plans to divest its China Immunodiagnostics business. Revenue was $730 million, up from $720 million a year earlier, with GAAP earnings per share from continuing operations of $0.48 versus $0.47. Adjusted EPS from continuing operations rose to $1.41 from $1.18, and adjusted operating profit margin increased to 28.9% from 26.6%. GAAP operating income was $89 million, including $16 million of tariff-related refunds.
On a pro forma basis excluding the China Immunodiagnostics business (China IDX), revenue was $711 million with 4% pro forma revenue growth and 3% pro forma organic revenue growth. Diagnostics grew strongly while Life Sciences declined modestly. The company entered a definitive agreement to sell China IDX, which represented approximately 6% of 2025 revenue, for up to $200 million, subject to adjustments and closing conditions, and expects the transaction to close by the end of 2027. Pro forma adjusted EPS for 2026 is guided to $5.30–$5.40 on pro forma revenue of $2.83–$2.86 billion; operating cash flow from continuing operations for the first half of 2026 was $317.8 million.
Revvity, Inc. executive Anita Gonzales, Vice President and CAO, sold 85 shares of Common Stock on July 20, 2026 at $109.48 per share. The transaction occurred under a Rule 10b5-1 trading plan adopted on November 7, 2025, leaving her with 7,201 shares held directly.
Anita Gonzales, a holder of RVTY common stock, has filed a notice of proposed sale under Rule 144. The filing lists a planned sale of 85 shares of common stock through Fidelity Brokerage Services LLC on 07/20/2026 on the NYSE, with a stated value of $9,305.80. These shares were acquired on 04/15/2022 via restricted stock vesting as compensation from the issuer. The filing also notes a prior sale in the last three months of 80 shares of common stock on 04/20/2026 for $7,424.00.
Revvity, Inc. is removing its 1.875% Notes due 2026 from listing and registration on the New York Stock Exchange LLC under Section 12(b) of the Securities Exchange Act of 1934. The Exchange and the issuer each state they have complied with the applicable requirements of 17 CFR 240.12d2-2(b) and 12d2-2(c) for this action.